Overview

Protective Effect of Ulinastatin and Thymosin 1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)

Status:
ENROLLING_BY_INVITATION

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 in addition to antiinflammatory treatment may be beneficial. This study was designed to test the hypothesis that the administration of Ulinastatin and Thymosin 1 during the acute phase of AAS will result in a reduced incidence of SIRS and MODS.

Phase:

Details

Lead Sponsor:

Nanjing Medical University

Collaborators:

Beijing Anzhen Hospital
Shanghai East Hospital,Tongji University School of Medicine
The First Affiliated Hospital of Guangzhou Medical University
West China Hospital

Treatments:

urinastatin